KAREN MANN-BROWN: Open Payments
NPI 1376696831 · FLORENCE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,605 in 120 payments from 35 companies in 2025. Trend: 2023 $2,612 · 2024 $2,573 · 2025 $2,605
Food & beverage: $2,506Education: $99
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 20 | $400 |
| AstraZeneca Pharmaceuticals LP | 11 | $347 |
| Janssen Biotech, Inc. | 7 | $233 |
| Merck Sharp & Dohme LLC | 8 | $178 |
| BeOne Medicines USA, Inc. | 9 | $164 |
| PFIZER INC. | 7 | $125 |
| Celgene Corporation | 5 | $114 |
| E.R. Squibb & Sons, L.L.C. | 6 | $98 |
| Incyte Corporation | 4 | $88 |
| ABBVIE INC. | 5 | $86 |
Products named: KISQALI, IMFINZI, RYBREVANT, KEYTRUDA, REBLOZYL, BRUKINSA, PLUVICTO, XTANDI.
Industry payments across AL — which companies pay providers there.
